Dale Vanderputten

Biography

 Dr. Dale VanderPutten, MBA, PhD has been Chief Scientific Officer of Nutra Pharma Corporation since July 27, 2016. Dr. VanderPutten has been Chief Executive Officer and Chief Scientific Officer of the biotechnology company Omnia Biologics, Inc., headquartered in Rockville, MD since 2003. From 1999 to 2003, he was Chief Operating Officer and Chief Scientific Officer of cancer gene therapy company DirectGene, Inc., headquartered in Annapolis, MD. Dr. VanderPutten has held scientific and technology development positions in government, academia and industry from 1980 to 1999 including at the National Institutes of Health, University of Maryland and Proteome Sciences, plc. Dr. VanderPutten received a Bachelor of Sciences degree in Biology and Chemistry from the American University, in Washington, DC in 1982, a PhD in Genetics from the George Washington University in 1993 and an MBA from the University of Maryland in 1996. He did his doctoral and post-doctoral training in molecular neuro-biology at the National Institutes of Health.

Research Interest

Omnia Biologics, Inc. provides manufacturing services and process development services for companies engaged in the development of novel biologics. It produces preclinical and GMP Phase I/II clinical materials used in vaccine and gene therapy applications. The company also provides cell and virus banking, and aseptic filling of viral and non-viral products. It offers its services for preclinical gene therapeutics, commercial recombinant proteins, viral based products, and cell therapeutics